Interprofessional Collaboration to Prevent Hospital-Acquired Pneumonia (HAP)

https://scholarworks.moreheadstate.edu/student_scholarship_posters/1138/thumbnail.jp

Medication use, renin-angiotensin system inhibitors, and acute care utilization after hospitalization in patients with chronic kidney disease.

OBJECTIVES: The aims of this secondary analysis were to: (a) characterize medication use following hospital discharge for patients with chronic kidney disease (CKD), and (b) investigate relationships of medication use with the primary composite outcome of acute care utilization 90 days after hospitalization. METHODS: The CKD-Medication Intervention Trial (CKD-MIT) enrolled acutely ill hospitalized patients with CKD stages 3-5 not dialyzed (CKD 3-5 ND). In this post hoc analysis, data for medication use were characterized, and the relationship of medication use with the primary outcome was evaluated using Cox proportional hazards models. RESULTS: Participants were taking a mean of 12.6 (standard deviation=5.1) medications, including medications from a wide variety of medication classes. Nearly half of study participants were taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB). ACE inhibitor/ARB use was associated with decreased risk of the primary outcome (hazard ratio=0.51; 95% confidence interval 0.28-0.95; CONCLUSIONS: A large number, variety, and complexity of medications were used by hospitalized patients with CKD 3-5 ND. ACE inhibitor or ARB use at hospital discharge was associated with a decreased risk of 90-day acute care utilization

Alzheimer’s Disease: A Look at Current and Future Treatment Options

Alzheimer’s disease (AD) is the most common form of dementia known today, with more than 5.2 million people suffering from this condition in the United States alone. This number is expected to rise to approximately 13.8 million by 2050 unless therapies effective in slowing or preventing the disease are developed. There are currently five FDA-approved medications for the treatment of AD symptoms. Four of these medications fall into a class of drugs known as cholinesterase inhibitors. The fifth medication, memantine, falls into a separate drug class. Because these two classes of drugs have significantly different effects on the body, they can be used together in what is known as combination therapy. The overall goal of this project was to determine whether combination therapy is more effective than cholinesterase monotherapy for treating AD and to identify new types of AD medications that are currently under development. In order to answer these questions, a literature review was conducted. This literature review focused on information from the National Institute of Health, Alzheimer’s Association, and peer-reviewed journals that were published in the last ten years

Extrathymic Aire-expressing cells support maternal-fetal tolerance

Healthy pregnancy requires tolerance to fetal alloantigens as well as syngeneic embryonic and placental antigens. Given the importance of the autoimmune regulator (Aire) gene in self-tolerance, we investigated the role of Aire-expressing cells in maternal-fetal tolerance. We report that maternal ablation of Aire-expressing (Aire +) cells during early mouse pregnancy caused intrauterine growth restriction (IUGR) in both allogeneic and syngeneic pregnancies. This phenotype is immune mediated, as IUGR was rescued in Rag1-deficient mice, and involved a memory response, demonstrated by recurrence of severe IUGR in second pregnancies. Single-cell RNA sequencing demonstrated that Aire + cell depletion in pregnancy results in expansion of activated T cells, particularly T follicular helper cells. Unexpectedly, selective ablation of either Aire-expressing medullary thymic epithelial cells or extrathymic Aire-expressing cells (eTACs) mapped the IUGR phenotype exclusively to eTACs. Thus, we report a previously undescribed mechanism for the maintenance of maternal-fetal immune homeostasis and demonstrate that eTACs protect the conceptus from immune-mediated IUGR

Validation of a murine proteome-wide phage display library for identification of autoantibody specificities

Autoimmunity is characterized by loss of tolerance to tissue-specific as well as systemic antigens, resulting in complex autoantibody landscapes. Here, we introduce and extensively validate the performance characteristics of a murine proteome-wide library for phage display immunoprecipitation and sequencing (PhIP-seq) in profiling mouse autoantibodies. This library was validated using 7 genetically distinct mouse lines across a spectrum of autoreactivity. Mice deficient in antibody production (Rag2-/- and μMT) were used to model nonspecific peptide enrichments, while cross-reactivity was evaluated using anti-ovalbumin B cell receptor-restricted OB1 mice as a proof of principle. The PhIP-seq approach was then utilized to interrogate 3 distinct autoimmune disease models. First, serum from Lyn-/- IgD+/- mice with lupus-like disease was used to identify nuclear and apoptotic bleb reactivities. Second, serum from nonobese diabetic (NOD) mice, a polygenic model of pancreas-specific autoimmunity, was enriched in peptides derived from both insulin and predicted pancreatic proteins. Lastly, Aire-/- mouse sera were used to identify numerous autoantigens, many of which were also observed in previous studies of humans with autoimmune polyendocrinopathy syndrome type 1 carrying recessive mutations in AIRE. These experiments support the use of murine proteome-wide PhIP-seq for antigenic profiling and autoantibody discovery, which may be employed to study a range of immune perturbations in mouse models of autoimmunity profiling

REVIEW: SOLUTIONS FOR GRAND CHALLENGES IN GOAT AND SHEEP PRODUCTION INDUSTRY

Goats and sheep are valuable as they are a source of meat, milk, fleece, and other products. These livestock are also important both for agriculture and biomedical research. However, the efficient, sustainable, and profitable production of these small ruminants faces major obstacles. Hence, this review analyzes these major challenges specifically, their negative impacts on the industry, and suggests some science-based solutions to overcome them. Those challenged areas are education and training, research, translational research/biotechnology, goat and sheep health, and maintenance of an economically sustainable agribusiness. The suggested solutions include the effective teaching of goat and sheep science to the next generation and public empowerment, support for innovative and translational research, disease prevention and treatment, support for technology transfer, and development of sound agribusiness practices. This review is helpful particularly for scientists, students, and the goat and sheep producers. In general, these information on the current state of goat and sheep agriculture will also help the public to better understand and appreciate the challenges met and opportunities provided in small ruminant production enterprises